{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T15:28:42Z","timestamp":1791646122476,"version":"4.3.4"},"reference-count":172,"publisher":"MDPI AG","issue":"14","license":[{"start":{"date-parts":[[2022,7,16]],"date-time":"2022-07-16T00:00:00Z","timestamp":1657929600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"China Postdoctoral Science Foundation","award":["2021m690095"],"award-info":[{"award-number":["2021m690095"]}]},{"name":"China Postdoctoral Science Foundation","award":["202110475070"],"award-info":[{"award-number":["202110475070"]}]},{"name":"China Postdoctoral Science Foundation","award":["202110475090"],"award-info":[{"award-number":["202110475090"]}]},{"name":"China Postdoctoral Science Foundation","award":["202110475006"],"award-info":[{"award-number":["202110475006"]}]},{"name":"China Postdoctoral Science Foundation","award":["202110475067"],"award-info":[{"award-number":["202110475067"]}]},{"name":"China Postdoctoral Science Foundation","award":["81870591"],"award-info":[{"award-number":["81870591"]}]},{"name":"National Innovation and Entrepreneurship Training Program for College students","award":["2021m690095"],"award-info":[{"award-number":["2021m690095"]}]},{"name":"National Innovation and Entrepreneurship Training Program for College students","award":["202110475070"],"award-info":[{"award-number":["202110475070"]}]},{"name":"National Innovation and Entrepreneurship Training Program for College students","award":["202110475090"],"award-info":[{"award-number":["202110475090"]}]},{"name":"National Innovation and Entrepreneurship Training Program for College students","award":["202110475006"],"award-info":[{"award-number":["202110475006"]}]},{"name":"National Innovation and Entrepreneurship Training Program for College students","award":["202110475067"],"award-info":[{"award-number":["202110475067"]}]},{"name":"National Innovation and Entrepreneurship Training Program for College students","award":["81870591"],"award-info":[{"award-number":["81870591"]}]},{"name":"National Natural Science Foundation of China","award":["2021m690095"],"award-info":[{"award-number":["2021m690095"]}]},{"name":"National Natural Science Foundation of China","award":["202110475070"],"award-info":[{"award-number":["202110475070"]}]},{"name":"National Natural Science Foundation of China","award":["202110475090"],"award-info":[{"award-number":["202110475090"]}]},{"name":"National Natural Science Foundation of China","award":["202110475006"],"award-info":[{"award-number":["202110475006"]}]},{"name":"National Natural Science Foundation of China","award":["202110475067"],"award-info":[{"award-number":["202110475067"]}]},{"name":"National Natural Science Foundation of China","award":["81870591"],"award-info":[{"award-number":["81870591"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Non-alcoholic fatty liver disease (NAFLD), one of the most common types of chronic liver disease, is strongly correlated with obesity, insulin resistance, metabolic syndrome, and genetic components. The pathological progression of NAFLD, consisting of non-alcoholic fatty liver (NAFL), non-alcoholic steatohepatitis (NASH), and liver cirrhosis, is characterized by a broad spectrum of clinical phenotypes. Although patients with mild NAFL are considered to show no obvious clinical symptoms, patients with long-term NAFL may culminate in NASH and further liver fibrosis. Even though various drugs are able to improve NAFLD, there are no FDA-approved medications that directly treat NAFLD. In this paper, the pathogenesis of NAFLD, the potential therapeutic targets, and their underlying mechanisms of action were reviewed.<\/jats:p>","DOI":"10.3390\/ijms23147841","type":"journal-article","created":{"date-parts":[[2022,7,17]],"date-time":"2022-07-17T22:57:06Z","timestamp":1658098626000},"page":"7841","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Pathogenesis and Therapeutic Strategies Related to Non-Alcoholic Fatty Liver Disease"],"prefix":"10.3390","volume":"23","author":[{"given":"Tieshan","family":"Teng","sequence":"first","affiliation":[{"name":"Institute of Biomedical Informatics, School of Basic Medical Sciences, Henan University, Kaifeng 475004, China"},{"name":"School of Nursing and Health, Henan University, Kaifeng 475004, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuai","family":"Qiu","sequence":"additional","affiliation":[{"name":"Institute of Biomedical Informatics, School of Basic Medical Sciences, Henan University, Kaifeng 475004, China"},{"name":"School of Nursing and Health, Henan University, Kaifeng 475004, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiming","family":"Zhao","sequence":"additional","affiliation":[{"name":"Institute of Biomedical Informatics, School of Basic Medical Sciences, Henan University, Kaifeng 475004, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siyuan","family":"Zhao","sequence":"additional","affiliation":[{"name":"Institute of Biomedical Informatics, School of Basic Medical Sciences, Henan University, Kaifeng 475004, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dequan","family":"Sun","sequence":"additional","affiliation":[{"name":"Institute of Biomedical Informatics, School of Basic Medical Sciences, Henan University, Kaifeng 475004, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingzhu","family":"Hou","sequence":"additional","affiliation":[{"name":"Institute of Biomedical Informatics, School of Basic Medical Sciences, Henan University, Kaifeng 475004, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yihang","family":"Li","sequence":"additional","affiliation":[{"name":"Institute of Biomedical Informatics, School of Basic Medical Sciences, Henan University, Kaifeng 475004, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke","family":"Zhou","sequence":"additional","affiliation":[{"name":"Institute of Biomedical Informatics, School of Basic Medical Sciences, Henan University, Kaifeng 475004, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xixi","family":"Yu","sequence":"additional","affiliation":[{"name":"Institute of Biomedical Informatics, School of Basic Medical Sciences, Henan University, Kaifeng 475004, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changyong","family":"Yang","sequence":"additional","affiliation":[{"name":"Institute of Biomedical Informatics, School of Basic Medical Sciences, Henan University, Kaifeng 475004, China"},{"name":"School of Nursing and Health, Henan University, Kaifeng 475004, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanzhang","family":"Li","sequence":"additional","affiliation":[{"name":"Institute of Biomedical Informatics, School of Basic Medical Sciences, Henan University, Kaifeng 475004, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,7,16]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Marchisello, S., Di Pino, A., Scicali, R., Urbano, F., Piro, S., Purrello, F., and Rabuazzo, A.M. (2019). Pathophysiological, Molecular and Therapeutic Issues of Nonalcoholic Fatty Liver Disease: An Overview. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20081948"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1056\/NEJMra011775","article-title":"Nonalcoholic fatty liver disease","volume":"346","author":"Angulo","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/nrgastro.2017.109","article-title":"Global burden of NAFLD and NASH: Trends, predictions, risk factors and prevention","volume":"15","author":"Younossi","year":"2018","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1002\/hep.31040","article-title":"Attributable Fractions of NAFLD for Mortality in the United States: Results From NHANES III With 27 Years of Follow-up","volume":"72","author":"Alvarez","year":"2019","journal-title":"Hepatology"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1002\/hep.30251","article-title":"Global Perspectives on Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis","volume":"69","author":"Younossi","year":"2019","journal-title":"Hepatology"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/S2468-1253(19)30039-1","article-title":"Prevalence, incidence, and outcome of non-alcoholic fatty liver disease in Asia, 1999-2019: A systematic review and meta-analysis","volume":"4","author":"Li","year":"2019","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1016\/S0140-6736(09)60746-7","article-title":"Global burden of disease and injury and economic cost attributable to alcohol use and alcohol-use disorders","volume":"373","author":"Rehm","year":"2009","journal-title":"Lancet"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Calzadilla Bertot, L., and Adams, L.A. (2016). The Natural Course of Non-Alcoholic Fatty Liver Disease. Int. J. Mol. Sci., 17.","DOI":"10.3390\/ijms17050774"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.jhep.2017.09.003","article-title":"Genetics and epigenetics of NAFLD and NASH: Clinical impact","volume":"68","author":"Eslam","year":"2018","journal-title":"J. Hepatol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1126\/science.1204265","article-title":"Human fatty liver disease: Old questions and new insights","volume":"332","author":"Cohen","year":"2011","journal-title":"Science"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.jhep.2016.05.013","article-title":"Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: A meta-analysis","volume":"65","author":"Targher","year":"2016","journal-title":"J. Hepatol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.jhep.2017.09.021","article-title":"Hypertension, diabetes, atherosclerosis and NASH: Cause or consequence?","volume":"68","author":"Lonardo","year":"2018","journal-title":"J. Hepatol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/S0016-5085(98)70599-2","article-title":"Steatohepatitis: A tale of two \u201chits\u201d?","volume":"114","author":"Day","year":"1998","journal-title":"Gastroenterology"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1038\/s41591-018-0104-9","article-title":"Mechanisms of NAFLD development and therapeutic strategies","volume":"24","author":"Friedman","year":"2018","journal-title":"Nat. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1016\/j.metabol.2015.12.012","article-title":"The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD)","volume":"65","author":"Buzzetti","year":"2016","journal-title":"Metabolism"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.jhep.2017.11.014","article-title":"Lipotoxicity and the gut-liver axis in NASH pathogenesis","volume":"68","author":"Marra","year":"2018","journal-title":"J. Hepatol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1038\/s41575-019-0239-2","article-title":"What\u2019s new in NAFLD pathogenesis, biomarkers and treatment?","volume":"17","author":"Byrne","year":"2020","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1038\/nrgastro.2017.38","article-title":"Mechanisms of hepatic stellate cell activation","volume":"14","author":"Tsuchida","year":"2017","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"729","DOI":"10.21037\/atm-20-4354","article-title":"Non-alcoholic fatty liver disease (NAFLD)\/non-alcoholic steatohepatitis (NASH)-related liver fibrosis: Mechanisms, treatment and prevention","volume":"9","author":"Tacke","year":"2021","journal-title":"Ann. Transl. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"7312","DOI":"10.3748\/wjg.v20.i23.7312","article-title":"Pathogenesis of liver cirrhosis","volume":"20","author":"Zhou","year":"2014","journal-title":"World J. Gastroenterol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1002\/hep.31518","article-title":"Multiple Parallel Hits Hypothesis in Nonalcoholic Fatty Liver Disease: Revisited After a Decade","volume":"73","author":"Tilg","year":"2021","journal-title":"Hepatology"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.arcmed.2020.11.010","article-title":"Epidemiology, Pathogenesis, Diagnosis and Emerging Treatment of Nonalcoholic Fatty Liver Disease","volume":"52","author":"Makri","year":"2021","journal-title":"Arch. Med. Res."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Fujii, H., Kawada, N., and Japan Study Group Of Nafld, J.-N. (2020). The Role of Insulin Resistance and Diabetes in Nonalcoholic Fatty Liver Disease. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21113863"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/j.cell.2018.09.055","article-title":"Microbially Produced Imidazole Propionate Impairs Insulin Signaling through mTORC1","volume":"175","author":"Koh","year":"2018","journal-title":"Cell"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.1053\/j.gastro.2020.02.033","article-title":"TMAVA, a Metabolite of Intestinal Microbes, Is Increased in Plasma From Patients With Liver Steatosis, Inhibits \u03b3-Butyrobetaine Hydroxylase, and Exacerbates Fatty Liver in Mice","volume":"158","author":"Zhao","year":"2020","journal-title":"Gastroenterology"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1159\/000518407","article-title":"The Role of Innate Immune Cells in Nonalcoholic Fatty Liver Disease","volume":"14","author":"Nati","year":"2022","journal-title":"J. Innate Immun."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"bqab157","DOI":"10.1210\/endocr\/bqab157","article-title":"SGLT2 Inhibition for Cardiovascular Diseases, Chronic Kidney Disease, and NAFLD","volume":"162","author":"Ala","year":"2021","journal-title":"Endocrinology"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1007\/s00535-017-1415-1","article-title":"Current and future pharmacological therapies for NAFLD\/NASH","volume":"53","author":"Sumida","year":"2018","journal-title":"J. Gastroenterol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1111\/bph.14859","article-title":"Delayed intervention with a novel SGLT2 inhibitor NGI001 suppresses diet-induced metabolic dysfunction and non-alcoholic fatty liver disease in mice","volume":"177","author":"Chiang","year":"2020","journal-title":"Br. J. Pharm."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.ebiom.2017.05.028","article-title":"SGLT2 Inhibition by Empagliflozin Promotes Fat Utilization and Browning and Attenuates Inflammation and Insulin Resistance by Polarizing M2 Macrophages in Diet-induced Obese Mice","volume":"20","author":"Xu","year":"2017","journal-title":"EBioMedicine"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1136\/gutjnl-2021-324305","article-title":"Novel therapeutic targets for cholestatic and fatty liver disease","volume":"71","author":"Trauner","year":"2022","journal-title":"Gut"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"24231","DOI":"10.1074\/jbc.M116.759795","article-title":"Perilipin-2 Deletion Impairs Hepatic Lipid Accumulation by Interfering with Sterol Regulatory Element-binding Protein (SREBP) Activation and Altering the Hepatic Lipidome","volume":"291","author":"Libby","year":"2016","journal-title":"J. Biol. Chem."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"G726","DOI":"10.1152\/ajpgi.00436.2015","article-title":"Liver-specific loss of Perilipin 2 alleviates diet-induced hepatic steatosis, inflammation, and fibrosis","volume":"310","author":"Najt","year":"2016","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/nature05449","article-title":"The nuclear receptor LXR is a glucose sensor","volume":"445","author":"Mitro","year":"2007","journal-title":"Nature"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1053\/j.gastro.2007.11.037","article-title":"Hepatic fatty acid transporter Cd36 is a common target of LXR, PXR, and PPARgamma in promoting steatosis","volume":"134","author":"Zhou","year":"2008","journal-title":"Gastroenterology"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"8071093","DOI":"10.1155\/2018\/8071093","article-title":"Liver X Receptor Inverse Agonist SR9243 Suppresses Nonalcoholic Steatohepatitis Intrahepatic Inflammation and Fibrosis","volume":"2018","author":"Huang","year":"2018","journal-title":"Biomed. Res. Int."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1111\/apt.13981","article-title":"Randomised clinical trial: The efficacy and safety of oltipraz, a liver X receptor alpha-inhibitory dithiolethione in patients with non-alcoholic fatty liver disease","volume":"45","author":"Kim","year":"2017","journal-title":"Aliment. Pharm. Ther."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"E1796","DOI":"10.1073\/pnas.1520686113","article-title":"Acetyl-CoA carboxylase inhibition by ND-630 reduces hepatic steatosis, improves insulin sensitivity, and modulates dyslipidemia in rats","volume":"113","author":"Harriman","year":"2016","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1080\/13543784.2020.1668374","article-title":"GS-0976 (Firsocostat): An investigational liver-directed acetyl-CoA carboxylase (ACC) inhibitor for the treatment of non-alcoholic steatohepatitis (NASH)","volume":"29","author":"Alkhouri","year":"2020","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1016\/j.cgh.2018.04.042","article-title":"Acetyl-CoA Carboxylase Inhibitor GS-0976 for 12 Weeks Reduces Hepatic De Novo Lipogenesis and Steatosis in Patients With Nonalcoholic Steatohepatitis","volume":"16","author":"Lawitz","year":"2018","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1111\/dom.14272","article-title":"Inhibition of fatty acid synthase with FT-4101 safely reduces hepatic de novo lipogenesis and steatosis in obese subjects with non-alcoholic fatty liver disease: Results from two early-phase randomized trials","volume":"23","author":"Beysen","year":"2021","journal-title":"Diabetes Obes. Metab."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1053\/j.gastro.2021.07.025","article-title":"TVB-2640 (FASN Inhibitor) for the Treatment of Nonalcoholic Steatohepatitis: FASCINATE-1, a Randomized, Placebo-Controlled Phase 2a Trial","volume":"161","author":"Loomba","year":"2021","journal-title":"Gastroenterology"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1002\/hep.31000","article-title":"Fatty Acid Synthase Inhibitor TVB-2640 Reduces Hepatic de Novo Lipogenesis in Males With Metabolic Abnormalities","volume":"72","author":"Gaballah","year":"2020","journal-title":"Hepatology"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/j.bbrc.2020.01.143","article-title":"MicroRNA-103 represses hepatic de novo lipogenesis and alleviates NAFLD via targeting FASN and SCD1","volume":"524","author":"Zhang","year":"2020","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.tem.2017.05.004","article-title":"AMPK as a Therapeutic Target for Treating Metabolic Diseases","volume":"28","author":"Day","year":"2017","journal-title":"Trends Endocrinol. Metab."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.ebiom.2018.01.008","article-title":"AMPK Re-Activation Suppresses Hepatic Steatosis but its Downregulation Does Not Promote Fatty Liver Development","volume":"28","author":"Boudaba","year":"2018","journal-title":"EBioMedicine"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.freeradbiomed.2019.06.019","article-title":"Berberine attenuates nonalcoholic hepatic steatosis through the AMPK-SREBP-1c-SCD1 pathway","volume":"141","author":"Zhu","year":"2019","journal-title":"Free Radic. Biol. Med."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1111\/j.1745-7254.2008.00807.x","article-title":"Resveratrol improves non-alcoholic fatty liver disease by activating AMP-activated protein kinase","volume":"29","author":"Shang","year":"2008","journal-title":"Acta Pharm. Sin."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.bbrc.2016.03.019","article-title":"Demethyleneberberine attenuates non-alcoholic fatty liver disease with activation of AMPK and inhibition of oxidative stress","volume":"472","author":"Qiang","year":"2016","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"3030","DOI":"10.1016\/j.bbagen.2016.09.028","article-title":"Pleiotropic properties of ASK1","volume":"1861","author":"Sakauchi","year":"2017","journal-title":"Biochim. Biophys. Acta Gen. Subj."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"e10124","DOI":"10.15252\/emmm.201810124","article-title":"Liver ASK1 protects from non-alcoholic fatty liver disease and fibrosis","volume":"11","author":"Challa","year":"2019","journal-title":"EMBO Mol. Med."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1002\/hep.30198","article-title":"Dual-Specificity Phosphatase 9 Protects Against Nonalcoholic Fatty Liver Disease in Mice Through ASK1 Suppression","volume":"69","author":"Ye","year":"2019","journal-title":"Hepatology"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"119716","DOI":"10.1016\/j.lfs.2021.119716","article-title":"Silent information regulator 1 suppresses epithelial-to-mesenchymal transition in lung cancer cells via its regulation of mitochondria status","volume":"280","author":"Zhang","year":"2021","journal-title":"Life Sci."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/j.drudis.2010.07.001","article-title":"Role of Sirtuin 1 in metabolic regulation","volume":"15","author":"Silva","year":"2010","journal-title":"Drug Discov. Today"},{"key":"ref_55","first-page":"88","article-title":"Sirtuin 1 signaling and alcoholic fatty liver disease","volume":"4","author":"You","year":"2015","journal-title":"Hepatobiliary Surg. Nutr."},{"key":"ref_56","first-page":"410","article-title":"Direct evidence of sirtuin downregulation in the liver of non-alcoholic fatty liver disease patients","volume":"44","author":"Wu","year":"2014","journal-title":"Ann. Clin. Lab. Sci."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s13105-015-0392-1","article-title":"Resveratrol improves high-fat diet induced insulin resistance by rebalancing subsarcolemmal mitochondrial oxidation and antioxidantion","volume":"71","author":"Haohao","year":"2015","journal-title":"J. Physiol. Biochem."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1038\/nm.3821","article-title":"Resveratrol activates duodenal Sirt1 to reverse insulin resistance in rats through a neuronal network","volume":"21","author":"Rasmussen","year":"2015","journal-title":"Nat. Med."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.3748\/wjg.v26.i18.2203","article-title":"Folic acid attenuates high-fat diet-induced steatohepatitis via deacetylase SIRT1-dependent restoration of PPAR\u03b1","volume":"26","author":"Xin","year":"2020","journal-title":"World J. Gastroenterol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"108554","DOI":"10.1016\/j.jnutbio.2020.108554","article-title":"High folic acid intake increases methylation-dependent expression of Lsr and dysregulates hepatic cholesterol homeostasis","volume":"88","author":"Leclerc","year":"2021","journal-title":"J. Nutr. Biochem."},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Salman, M., Kamel, M.A., El-Nabi, S.E.H., Ismail, A.H.A., Ullah, S., Al-Ghamdi, A., Hathout, H.M.R., and El-Garawani, I.M. (2022). The regulation of HBP1, SIRT1, and SREBP-1c genes and the related microRNAs in non-alcoholic fatty liver rats: The association with the folic acid anti-steatosis. PLoS ONE, 17.","DOI":"10.1371\/journal.pone.0265455"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"780496","DOI":"10.3389\/fphar.2022.780496","article-title":"The NLRP3 Inflammasome in Non-Alcoholic Fatty Liver Disease and Steatohepatitis: Therapeutic Targets and Treatment","volume":"13","author":"Yu","year":"2022","journal-title":"Front. Pharm."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/j.jhep.2017.01.022","article-title":"NLRP3 inflammasome blockade reduces liver inflammation and fibrosis in experimental NASH in mice","volume":"66","author":"Mridha","year":"2017","journal-title":"J. Hepatol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.intimp.2019.02.016","article-title":"The selective NLRP3 inflammasome inhibitor MCC950 alleviates cholestatic liver injury and fibrosis in mice","volume":"70","author":"Qu","year":"2019","journal-title":"Int. Immunopharmacol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1111\/bph.14938","article-title":"Naringenin attenuates non-alcoholic fatty liver disease by down-regulating the NLRP3\/NF-\u03baB pathway in mice","volume":"177","author":"Wang","year":"2020","journal-title":"Br. J. Pharm."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1038\/nm.2208","article-title":"Allosteric inhibition of lysyl oxidase-like-2 impedes the development of a pathologic microenvironment","volume":"16","author":"Spangler","year":"2010","journal-title":"Nat. Med."},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"Puente, A., Fortea, J.I., Cabezas, J., Arias Loste, M.T., Iruzubieta, P., Llerena, S., Huelin, P., F\u00e1brega, E., and Crespo, J. (2019). LOXL2-A New Target in Antifibrogenic Therapy?. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20071634"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1042\/CS20170175","article-title":"Insulin resistance promotes Lysyl Oxidase Like 2 induction and fibrosis accumulation in non-alcoholic fatty liver disease","volume":"131","author":"Dongiovanni","year":"2017","journal-title":"Clin. Sci."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.bioorg.2014.07.003","article-title":"Human lysyl oxidase-like 2","volume":"57","author":"Moon","year":"2014","journal-title":"Bioorganic Chem."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1111\/jcmm.14074","article-title":"The lysyl oxidase like 2\/3 enzymatic inhibitor, PXS-5153A, reduces crosslinks and ameliorates fibrosis","volume":"23","author":"Schilter","year":"2019","journal-title":"J. Cell Mol. Med."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1172\/JCI73722","article-title":"Vascular adhesion protein-1 promotes liver inflammation and drives hepatic fibrosis","volume":"125","author":"Weston","year":"2015","journal-title":"J. Clin. Investig."},{"key":"ref_72","first-page":"1757","article-title":"Circulating vascular adhesion protein-1(VAP-1): A possible biomarker for liver fibrosis associated with chronic hepatitis B and C","volume":"51","author":"Serin","year":"2020","journal-title":"Braz. J. Microbiol. Publ. Braz. Soc. Microbiol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"931","DOI":"10.4254\/wjh.v12.i11.931","article-title":"Inhibition of vascular adhesion protein-1 modifies hepatic steatosis in vitro and in vivo","volume":"12","author":"Shepherd","year":"2020","journal-title":"World J. Hepatol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1136\/gutjnl-2016-312354","article-title":"Vascular adhesion protein-1 is elevated in primary sclerosing cholangitis, is predictive of clinical outcome and facilitates recruitment of gut-tropic lymphocytes to liver in a substrate-dependent manner","volume":"67","author":"Trivedi","year":"2018","journal-title":"Gut"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"102189","DOI":"10.1016\/j.coph.2022.102189","article-title":"GLP-1\u2014Incretin and pleiotropic hormone with pharmacotherapy potential. Increasing secretion of endogenous GLP-1 for diabetes and obesity therapy","volume":"63","author":"Holst","year":"2022","journal-title":"Curr. Opin. Pharmacol."},{"key":"ref_76","doi-asserted-by":"crossref","unstructured":"Mathiesen, D.S., Bagger, J.I., Bergmann, N.C., Lund, A., Christensen, M.B., Vilsb\u00f8ll, T., and Knop, F.K. (2019). The Effects of Dual GLP-1\/GIP Receptor Agonism on Glucagon Secretion-A Review. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20174092"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.2337\/dc19-1892","article-title":"Effects of Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide on Biomarkers of Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes","volume":"43","author":"Hartman","year":"2020","journal-title":"Diabetes Care"},{"key":"ref_78","first-page":"7372","article-title":"Liraglutide improves hepatic insulin resistance via the canonical Wnt signaling pathway","volume":"17","author":"Qin","year":"2018","journal-title":"Mol. Med. Rep."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/s00125-019-05065-8","article-title":"Effects of once-weekly semaglutide vs once-daily canagliflozin on body composition in type 2 diabetes: A substudy of the SUSTAIN 8 randomised controlled clinical trial","volume":"63","author":"McCrimmon","year":"2020","journal-title":"Diabetologia"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.phrs.2014.03.002","article-title":"The pharmacology of statins","volume":"88","author":"Sirtori","year":"2014","journal-title":"Pharm. Res."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.atherosclerosis.2019.02.028","article-title":"Statins and nonalcoholic fatty liver disease in the era of precision medicine: More friends than foes","volume":"284","author":"Nascimbeni","year":"2019","journal-title":"Atherosclerosis"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"2950","DOI":"10.1210\/jc.2017-00867","article-title":"Liver Safety of Statins in Prediabetes or T2DM and Nonalcoholic Steatohepatitis: Post Hoc Analysis of a Randomized Trial","volume":"102","author":"Bril","year":"2017","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1111\/bph.15427","article-title":"Activation of thyroid hormone receptor-\u03b2 improved disease activity and metabolism independent of body weight in a mouse model of non-alcoholic steatohepatitis and fibrosis","volume":"178","author":"Kannt","year":"2021","journal-title":"Br. J. Pharm."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1016\/S0140-6736(19)32517-6","article-title":"Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: A multicentre, randomised, double-blind, placebo-controlled, phase 2 trial","volume":"394","author":"Harrison","year":"2019","journal-title":"Lancet"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1089\/thy.2019.0007","article-title":"A Liver-Specific Thyromimetic, VK2809, Decreases Hepatosteatosis in Glycogen Storage Disease Type Ia","volume":"29","author":"Zhou","year":"2019","journal-title":"Thyroid Off. J. Am. Thyroid Assoc."},{"key":"ref_86","doi-asserted-by":"crossref","unstructured":"Luong, X.G., Stevens, S.K., Jekle, A., Lin, T.I., Gupta, K., Misner, D., Chanda, S., Mukherjee, S., Williams, C., and Stoycheva, A. (2020). Regulation of gene transcription by thyroid hormone receptor \u03b2 agonists in clinical development for the treatment of non-alcoholic steatohepatitis (NASH). PLoS ONE, 15.","DOI":"10.1101\/2020.09.25.312934"},{"key":"ref_87","doi-asserted-by":"crossref","unstructured":"Lee, G.Y., and Han, S.N. (2018). The Role of Vitamin E in Immunity. Nutrients, 10.","DOI":"10.3390\/nu10111614"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.pharmthera.2015.12.003","article-title":"Vitamin E therapy beyond cancer: Tocopherol versus tocotrienol","volume":"162","author":"Peh","year":"2016","journal-title":"Pharmacol. Ther."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.2337\/dc19-0167","article-title":"Role of Vitamin E for Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes: A Randomized Controlled Trial","volume":"42","author":"Bril","year":"2019","journal-title":"Diabetes Care"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"11","DOI":"10.2147\/HMER.S41258","article-title":"Treatment of nonalcoholic steatohepatitis with vitamins E and C: A pilot study","volume":"5","author":"Kawanaka","year":"2013","journal-title":"Hepatic Med. Evid. Res."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"193","DOI":"10.3945\/jn.113.185561","article-title":"Antioxidant supplements reduced oxidative stress and stabilized liver function tests but did not reduce inflammation in a randomized controlled trial in obese children and adolescents","volume":"144","author":"Murer","year":"2014","journal-title":"J. Nutr."},{"key":"ref_92","doi-asserted-by":"crossref","unstructured":"Perumpail, B.J., Li, A.A., John, N., Sallam, S., Shah, N.D., Kwong, W., Cholankeril, G., Kim, D., and Ahmed, A. (2018). The Role of Vitamin E in the Treatment of NAFLD. Diseases, 6.","DOI":"10.3390\/diseases6040086"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"c5702","DOI":"10.1136\/bmj.c5702","article-title":"Effects of vitamin E on stroke subtypes: Meta-analysis of randomised controlled trials","volume":"341","author":"Glynn","year":"2010","journal-title":"BMJ Clin. Res. Ed."},{"key":"ref_94","doi-asserted-by":"crossref","unstructured":"Oliver, C.J., and Myers, S.P. (2017). Validity of a Cochrane Systematic Review and meta-analysis for determining the safety of vitamin E. BMC Complementary Altern. Med., 17.","DOI":"10.1186\/s12906-017-1906-x"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.bbadis.2017.10.003","article-title":"Farnesoid X receptor: A \u201chomeostat\u201d for hepatic nutrient metabolism","volume":"1864","author":"Massafra","year":"2018","journal-title":"Biochim. Biophys. Acta Mol. Basis Dis."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/j.apsb.2019.02.004","article-title":"Ablation of gut microbiota alleviates obesity-induced hepatic steatosis and glucose intolerance by modulating bile acid metabolism in hamsters","volume":"9","author":"Sun","year":"2019","journal-title":"Acta Pharm. Sin. B"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1002\/oby.22440","article-title":"Bile Diversion Improves Metabolic Phenotype Dependent on Farnesoid X Receptor (FXR)","volume":"27","author":"Pierre","year":"2019","journal-title":"Obesity"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1002\/hep4.1368","article-title":"Tropifexor-Mediated Abrogation of Steatohepatitis and Fibrosis Is Associated With the Antioxidative Gene Expression Profile in Rodents","volume":"3","author":"Hernandez","year":"2019","journal-title":"Hepatol. Commun."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"179","DOI":"10.3748\/wjg.v24.i2.179","article-title":"Metabolic and hepatic effects of liraglutide, obeticholic acid and elafibranor in diet-induced obese mouse models of biopsy-confirmed nonalcoholic steatohepatitis","volume":"24","author":"Kristiansen","year":"2018","journal-title":"World J. Gastroenterol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1053\/j.gastro.2013.05.042","article-title":"Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease","volume":"145","author":"Mudaliar","year":"2013","journal-title":"Gastroenterology"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1002\/hep.31205","article-title":"Cilofexor, a Nonsteroidal FXR Agonist, in Patients With Noncirrhotic NASH: A Phase 2 Randomized Controlled Trial","volume":"72","author":"Patel","year":"2020","journal-title":"Hepatology"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1080\/13543784.2020.1763302","article-title":"Bile acid modulators for the treatment of nonalcoholic steatohepatitis (NASH)","volume":"29","author":"Fiorucci","year":"2020","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1046\/j.1523-1755.2002.00129.x","article-title":"Peroxisome proliferator-activated receptors (PPARs): Novel therapeutic targets in renal disease","volume":"61","author":"Broeders","year":"2002","journal-title":"Kidney Int."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/0005-2760(96)00066-5","article-title":"The peroxisome proliferator activated receptors (PPARS) and their effects on lipid metabolism and adipocyte differentiation","volume":"1302","author":"Schoonjans","year":"1996","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.jhep.2015.02.019","article-title":"PPAR\u03b1 gene expression correlates with severity and histological treatment response in patients with non-alcoholic steatohepatitis","volume":"63","author":"Francque","year":"2015","journal-title":"J. Hepatol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"142","DOI":"10.5551\/jat.39693","article-title":"A Novel Selective PPAR\u03b1 Modulator (SPPARM\u03b1), K-877 (Pemafibrate), Attenuates Postprandial Hypertriglyceridemia in Mice","volume":"25","author":"Sairyo","year":"2018","journal-title":"J. Atheroscler. Thromb."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.ejphar.2009.09.002","article-title":"PPARdelta ligand L-165041 ameliorates Western diet-induced hepatic lipid accumulation and inflammation in LDLR-\/- mice","volume":"622","author":"Lim","year":"2009","journal-title":"Eur. J. Pharm."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"2619","DOI":"10.1101\/gad.178434.111","article-title":"The nuclear receptor PPAR\u03b2\/\u03b4 programs muscle glucose metabolism in cooperation with AMPK and MEF2","volume":"25","author":"Gan","year":"2011","journal-title":"Genes Dev."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1002\/hep4.1072","article-title":"The selective peroxisome proliferator-activated receptor-delta agonist seladelpar reverses nonalcoholic steatohepatitis pathology by abrogating lipotoxicity in diabetic obese mice","volume":"1","author":"Haczeyni","year":"2017","journal-title":"Hepatol. Commun"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1080\/13543784.2020.1668375","article-title":"Elafibranor: A potential drug for the treatment of nonalcoholic steatohepatitis (NASH)","volume":"29","author":"Drenth","year":"2020","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1038\/nature03988","article-title":"A SUMOylation-dependent pathway mediates transrepression of inflammatory response genes by PPAR-gamma","volume":"437","author":"Pascual","year":"2005","journal-title":"Nature"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1002\/jlb.66.5.733","article-title":"The peroxisome proliferator-activated receptor(PPARgamma) as a regulator of monocyte\/macrophage function","volume":"66","author":"Ricote","year":"1999","journal-title":"J. Leukoc. Biol."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s00384-006-0112-y","article-title":"NF-kappaB\/PPAR gamma and\/or AP-1\/PPAR gamma \u2018on\/off\u2019 switches and induction of CBP in colon adenocarcinomas: Correlation with COX-2 expression","volume":"22","author":"Konstantinopoulos","year":"2007","journal-title":"Int. J. Colorectal Dis."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1038\/gt.2010.41","article-title":"PPARgamma is essential for protection against nonalcoholic steatohepatitis","volume":"17","author":"Wu","year":"2010","journal-title":"Gene Ther."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"44612","DOI":"10.1038\/srep44612","article-title":"Effect of modulation of PPAR-\u03b3 activity on Kupffer cells M1\/M2 polarization in the development of non-alcoholic fatty liver disease","volume":"7","author":"Luo","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"21117","DOI":"10.1038\/s41598-020-78342-x","article-title":"Saroglitazar in patients with non-alcoholic fatty liver disease and diabetic dyslipidemia: A prospective, observational, real world study","volume":"10","author":"Goyal","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1186\/s12933-020-01073-w","article-title":"Effect of saroglitazar 2 mg and 4 mg on glycemic control, lipid profile and cardiovascular disease risk in patients with type 2 diabetes mellitus: A 56-week, randomized, double blind, phase 3 study (PRESS XII study)","volume":"19","author":"Krishnappa","year":"2020","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1016\/j.jhep.2020.11.045","article-title":"Pan-PPAR agonist lanifibranor improves portal hypertension and hepatic fibrosis in experimental advanced chronic liver disease","volume":"74","author":"Robert","year":"2021","journal-title":"J. Hepatol."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1517\/14728222.2014.997711","article-title":"Targeting fibroblast growth factor 19 in liver disease: A potential biomarker and therapeutic target","volume":"19","author":"Liu","year":"2015","journal-title":"Expert Opin. Ther. Targets"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1080\/14728222.2021.1999416","article-title":"A short report on NGM282\/aldafermin for the treatment of nonalcoholic steatohepatitis (NASH)","volume":"25","author":"Roberts","year":"2021","journal-title":"Expert Opin. Ther. Targets"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1016\/S0140-6736(18)30474-4","article-title":"NGM282 for treatment of non-alcoholic steatohepatitis: A multicentre, randomised, double-blind, placebo-controlled, phase 2 trial","volume":"391","author":"Harrison","year":"2018","journal-title":"Lancet"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1146\/annurev-physiol-021115-105339","article-title":"Understanding the Physiology of FGF21","volume":"78","author":"Fisher","year":"2016","journal-title":"Annu. Rev. Physiol."},{"key":"ref_123","first-page":"441","article-title":"An Overview of FGF19 and FGF21: The Therapeutic Role in the Treatment of the Metabolic Disorders and Obesity","volume":"50","author":"Babaknejad","year":"2018","journal-title":"Horm. Metab. Res. Horm.-Und Stoffwechs. Horm. Metab."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.cmet.2019.01.004","article-title":"A Dozen Years of Discovery: Insights into the Physiology and Pharmacology of FGF21","volume":"29","author":"Kliewer","year":"2019","journal-title":"Cell Metab"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"e8791","DOI":"10.15252\/emmm.201708791","article-title":"FGF21 gene therapy as treatment for obesity and insulin resistance","volume":"10","author":"Jimenez","year":"2018","journal-title":"EMBO Mol. Med."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1080\/13543784.2020.1708898","article-title":"Pegbelfermin (BMS-986036): An investigational PEGylated fibroblast growth factor 21 analogue for the treatment of nonalcoholic steatohepatitis","volume":"29","author":"Verzijl","year":"2020","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.1016\/S0140-6736(18)31785-9","article-title":"Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: A randomised, double-blind, placebo-controlled, phase 2a trial","volume":"392","author":"Sanyal","year":"2019","journal-title":"Lancet"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"100057","DOI":"10.1016\/j.xcrm.2020.100057","article-title":"AKR-001, an Fc-FGF21 Analog, Showed Sustained Pharmacodynamic Effects on Insulin Sensitivity and Lipid Metabolism in Type 2 Diabetes Patients","volume":"1","author":"Kaufman","year":"2020","journal-title":"Cell Rep. Med."},{"key":"ref_129","first-page":"1858","article-title":"CCR1 and CCR5 promote hepatic fibrosis in mice","volume":"119","author":"Seki","year":"2009","journal-title":"J. Clin. Investig."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"213","DOI":"10.3389\/fphys.2012.00213","article-title":"The role of chemokines in acute liver injury","volume":"3","author":"Saiman","year":"2012","journal-title":"Front. Physiol."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"11035","DOI":"10.1021\/acs.jmedchem.9b00742","article-title":"Synthesis and Pharmacological Evaluation of Triazolopyrimidinone Derivatives as Noncompetitive, Intracellular Antagonists for CC Chemokine Receptors 2 and 5","volume":"62","author":"Dogan","year":"2019","journal-title":"J. Med. Chem."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1021\/ml500505q","article-title":"Discovery of a Potent and Orally Bioavailable Dual Antagonist of CC Chemokine Receptors 2 and 5","volume":"6","author":"Carter","year":"2015","journal-title":"ACS Med. Chem. Lett."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1111\/liv.12570","article-title":"The pan-caspase inhibitor Emricasan (IDN-6556) decreases liver injury and fibrosis in a murine model of non-alcoholic steatohepatitis","volume":"35","author":"Barreyro","year":"2015","journal-title":"Liver Int."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1111\/apt.15030","article-title":"Randomised clinical trial: Emricasan versus placebo significantly decreases ALT and caspase 3\/7 activation in subjects with non-alcoholic fatty liver disease","volume":"49","author":"Shiffman","year":"2019","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_135","doi-asserted-by":"crossref","unstructured":"Bral, M., Pawlick, R., Marfil-Garza, B., Dadheech, N., Hefler, J., Thiesen, A., and Shapiro, A.M.J. (2019). Pan-caspase inhibitor F573 mitigates liver ischemia reperfusion injury in a murine model. PLoS ONE, 14.","DOI":"10.1371\/journal.pone.0224567"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"9706","DOI":"10.3748\/wjg.v22.i44.9706","article-title":"Galectin-3 and IL-33\/ST2 axis roles and interplay in diet-induced steatohepatitis","volume":"22","author":"Pejnovic","year":"2016","journal-title":"World J. Gastroenterol."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/j.jhep.2010.09.020","article-title":"Galectin-3 ablation protects mice from diet-induced NASH: A major scavenging role for galectin-3 in liver","volume":"54","author":"Iacobini","year":"2011","journal-title":"J. Hepatol."},{"key":"ref_138","first-page":"303","article-title":"Hepatoprotective and Anti-fibrotic Agents: It\u2019s Time to Take the Next Step","volume":"6","author":"Weiskirchen","year":"2015","journal-title":"Front. Pharm."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1136\/gutjnl-2016-312431","article-title":"Current and upcoming pharmacotherapy for non-alcoholic fatty liver disease","volume":"66","author":"Rotman","year":"2017","journal-title":"Gut"},{"key":"ref_140","first-page":"1901","article-title":"Efficacy and Side Effect Profile of Different Formulations of Metformin: A Systematic Review and Meta-Analysis","volume":"12","author":"Grant","year":"2021","journal-title":"Diabetes Ther. Res. Treat. Educ. Diabetes Relat. Disord."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/osp4.84","article-title":"Liraglutide for weight management: A critical review of the evidence","volume":"3","author":"Mehta","year":"2017","journal-title":"Obes. Sci. Pract."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.jhep.2018.07.019","article-title":"Statins: Old drugs as new therapy for liver diseases?","volume":"70","author":"Pose","year":"2019","journal-title":"J. Hepatol."},{"key":"ref_143","doi-asserted-by":"crossref","unstructured":"Schwabl, P., Hambruch, E., Budas, G.R., Supper, P., Burnet, M., Liles, J.T., Birkel, M., Brusilovskaya, K., Konigshofer, P., and Peck-Radosavljevic, M. (2021). The Non-Steroidal FXR Agonist Cilofexor Improves Portal Hypertension and Reduces Hepatic Fibrosis in a Rat NASH Model. Biomedicines, 9.","DOI":"10.3390\/biomedicines9010060"},{"key":"ref_144","first-page":"213","article-title":"Emerging advances in the pharmacologic treatment of nonalcoholic steatohepatitis and related cirrhosis","volume":"35","author":"Sinakos","year":"2022","journal-title":"Ann. Gastroenterol."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"175","DOI":"10.3727\/105221619X15536120524171","article-title":"Current and Emerging Approaches for Nonalcoholic Steatohepatitis Treatment","volume":"19","author":"Chen","year":"2019","journal-title":"Gene Expr."},{"key":"ref_146","first-page":"1","article-title":"Semaglutide, cilofexor, and firsocostat for nonalcoholic steatohepatitis: A dance that may need more than one dancer","volume":"2","author":"Polyzos","year":"2022","journal-title":"Hormones"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/j.bbrc.2020.10.039","article-title":"Structural basis of tropifexor as a potent and selective agonist of farnesoid X receptor","volume":"534","author":"Jiang","year":"2021","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1016\/j.jhep.2021.01.013","article-title":"A randomized placebo-controlled trial of elafibranor in patients with primary biliary cholangitis and incomplete response to UDCA","volume":"74","author":"Schattenberg","year":"2021","journal-title":"J. Hepatol."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"106170","DOI":"10.1016\/j.cct.2020.106170","article-title":"A randomised, double-blind, placebo-controlled, multi-centre, dose-range, proof-of-concept, 24-week treatment study of lanifibranor in adult subjects with non-alcoholic steatohepatitis: Design of the NATIVE study","volume":"98","author":"Sven","year":"2020","journal-title":"Contemp. Clin. Trials"},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1002\/hep4.1209","article-title":"NGM282 for Treatment of Patients With Primary Biliary Cholangitis: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial","volume":"2","author":"Mayo","year":"2018","journal-title":"Hepatol. Commun."},{"key":"ref_151","first-page":"19","article-title":"Hepatic hormone FGF21 and its analogues in clinical trials","volume":"8","author":"Shao","year":"2022","journal-title":"Chronic Dis. Transl. Med."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/cts.12839","article-title":"Evolving Role for Pharmacotherapy in NAFLD\/NASH","volume":"14","author":"Attia","year":"2021","journal-title":"Clin. Transl. Sci."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/j.apsb.2018.11.004","article-title":"Combined obeticholic acid and apoptosis inhibitor treatment alleviates liver fibrosis","volume":"9","author":"Zhou","year":"2019","journal-title":"Acta Pharm. Sinica. B"},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1111\/apt.13816","article-title":"Randomised clinical study: GR-MD-02, a galectin-3 inhibitor, vs. placebo in patients having non-alcoholic steatohepatitis with advanced fibrosis","volume":"44","author":"Harrison","year":"2016","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"e450","DOI":"10.1097\/TXD.0000000000000885","article-title":"Efficacy and Safety of Empagliflozin in the Management of Diabetes Mellitus in Heart Transplant Recipients","volume":"5","author":"Cehic","year":"2019","journal-title":"Transplant. Direct"},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1016\/j.cgh.2020.05.021","article-title":"SGLT2 Inhibitors in Liver Patients","volume":"18","author":"Hsiang","year":"2020","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_157","doi-asserted-by":"crossref","unstructured":"Tacelli, M., Celsa, C., Magro, B., Giannetti, A., Pennisi, G., Spatola, F., and Petta, S. (2018). Antidiabetic Drugs in NAFLD: The Accomplishment of Two Goals at Once?. Pharmaceuticals, 11.","DOI":"10.3390\/ph11040121"},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"615409","DOI":"10.3389\/fendo.2021.615409","article-title":"Pioglitazone for NAFLD Patients With Prediabetes or Type 2 Diabetes Mellitus: A Meta-Analysis","volume":"12","author":"Lian","year":"2021","journal-title":"Front. Endocrinol."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.3892\/etm.2021.10601","article-title":"Future perspectives in diabesity treatment: Semaglutide, a glucagon-like peptide 1 receptor agonist (Review)","volume":"22","author":"Tilinca","year":"2021","journal-title":"Exp. Ther. Med."},{"key":"ref_160","doi-asserted-by":"crossref","unstructured":"Dibba, P., Li, A.A., Perumpail, B.J., John, N., Sallam, S., Shah, N.D., Kwong, W., Cholankeril, G., Kim, D., and Ahmed, A. (2018). Emerging Therapeutic Targets and Experimental Drugs for the Treatment of NAFLD. Diseases, 6.","DOI":"10.3390\/diseases6030083"},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"1801585","DOI":"10.1002\/advs.201801585","article-title":"Insights into the Epidemiology, Pathogenesis, and Therapeutics of Nonalcoholic Fatty Liver Diseases","volume":"6","author":"Yu","year":"2019","journal-title":"Adv. Sci."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1111\/j.1365-2036.2006.02926.x","article-title":"A pilot study of atorvastatin treatment in dyslipemid, non-alcoholic fatty liver patients","volume":"23","author":"Gisbert","year":"2006","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"284","DOI":"10.3904\/kjim.2019.043","article-title":"The utility of ezetimibe therapy in nonalcoholic fatty liver disease","volume":"34","author":"Jun","year":"2019","journal-title":"Korean J. Intern. Med."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1111\/1751-2980.12967","article-title":"Efficacy and safety of drugs for nonalcoholic steatohepatitis","volume":"22","author":"Shen","year":"2021","journal-title":"J. Dig. Dis."},{"key":"ref_165","first-page":"673","article-title":"NASH: A glance at the landscape of pharmacological treatment","volume":"15","author":"Brodosi","year":"2016","journal-title":"Ann. Hepatol."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.1007\/s00125-005-1893-1","article-title":"Adverse effects of left ventricular hypertrophy in the reduction of endpoints in NIDDM with the angiotensin II antagonist losartan (RENAAL) study","volume":"48","author":"Boner","year":"2005","journal-title":"Diabetologia"},{"key":"ref_167","first-page":"1","article-title":"Incidence of adverse events with telmisartan compared with ACE inhibitors: Evidence from a pooled analysis of clinical trials","volume":"6","author":"Mancia","year":"2012","journal-title":"Patient Prefer. Adherence"},{"key":"ref_168","doi-asserted-by":"crossref","unstructured":"Lake, J.E., Tseng, C.H., and Currier, J.S. (2013). A pilot study of telmisartan for visceral adiposity in HIV infection: The metabolic abnormalities, telmisartan, and HIV infection (MATH) trial. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0058135"},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"603926","DOI":"10.3389\/fphar.2020.603926","article-title":"Non-Alcoholic Steatohepatitis: A Review of Its Mechanism, Models and Medical Treatments","volume":"11","author":"Peng","year":"2020","journal-title":"Front. Pharmacol."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"159","DOI":"10.2147\/HMER.S188991","article-title":"A Review Of Current And Upcoming Treatment Modalities In Non-Alcoholic Fatty Liver Disease And Non-Alcoholic Steatohepatitis","volume":"11","author":"Ganguli","year":"2019","journal-title":"Hepatic Med. Evid. Res."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1159\/000519611","article-title":"Diagnostic and Therapy of Nonalcoholic Fatty Liver Disease: A Narrative Review","volume":"38","author":"Roeb","year":"2022","journal-title":"Visc. Med."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s43440-019-00020-1","article-title":"New therapeutic strategies in nonalcoholic fatty liver disease: A focus on promising drugs for nonalcoholic steatohepatitis","volume":"72","author":"Pydyn","year":"2020","journal-title":"Pharmacol. Rep."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/23\/14\/7841\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T23:51:52Z","timestamp":1760140312000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/23\/14\/7841"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,16]]},"references-count":172,"journal-issue":{"issue":"14","published-online":{"date-parts":[[2022,7]]}},"alternative-id":["ijms23147841"],"URL":"https:\/\/doi.org\/10.3390\/ijms23147841","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,16]]}}}